"We're on track," says Bayer chairman, despite 76% profit plunge in 3rd qtr

3 November 2008

Leverkusen, Germany-headquartered Bayer Group's profit for the third quarter of 2008 plunged by 76% year-on-year, on nearly flat sales, due to a 911.0-million euro ($1.13 billion) one-time tax benefit from local corporation tax reform inflating the comparitive figure.

Revenue rose 2% to 7.95 billion euros, whereas net income dropped to 277.0 million euros from 1.18 billion euros. A consensus of seven analysts polled by Bloomberg news had predicted 302.0 million euros. Core earnings per share, however, increased to 0.85 euros vs 0.81 euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight